Eli Lilly has signed a new research deal with BigHat Biosciences to co-develop next-generation antibody therapeutics, as the ...

Liraglutide is a peptide that has gained significant attention in scientific research due to its structural similarity to glucagon ... affinity to albumin, which might contribute to prolonged ...

dual oxyntomodulin analog agonist that functions as a glucagon-like peptide-1 receptor and glucagon receptor, for the treatment of obesity. In the 28-day, 36-subject MAD portion of the study ...

A groundbreaking study published in the journal Current Neuropharmacology highlights a concerning potential link between Glucagon-like Peptide-1 (GLP1) receptor agonists—widely used in blockbuster ...

UBT251 goes a step further by also inhibiting the glucagon receptor. Eli Lilly has already got a GIP, GLP-1 and glucagon agonist into late-stage development in the form of retatrutide, which was ...

Merck’s pipeline includes Phase 3 PCSK9 inhibitor and GLP-1/glucagon receptor agonist. China’s new tariffs just reignited the same market patterns that led to triple- and quadruple-digit wins ...

About UBT251UBT251 is a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon.

Both GLP-1 receptor agonists and SGLT2 inhibitors linked to reduced risk for ADRD, with no significant difference between them.

UBT251 is a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon. It has ...

THURSDAY, April 10, 2025 (HealthDay News) — Among U.S. adults without diabetes, the use of glucagon-like peptide 1 receptor ...